Controllable Synthesis of Fe2+-Rich Nanoworms for Combined Tumor Therapy Based on Ferroptosis and Immunotherapy
Source abstract
Abstract
Ferroptosis is an immunogenic form of cell death characterized by iron-dependent lipid peroxidation. The balance between Fe 2+ and Fe 3+ is crucial in inducing ferroptosis, where Fe 2+ primarily initiates the Fenton reaction to generate reactive oxygen species (ROS), resulting in lipid peroxidation and subsequent cell damage. However, the instability of Fe 2+, due to its susceptibility to oxidation into Fe 3+, poses challenges for effectively triggering ferroptosis. In this study, we report a synthetic method for creating Fe 2+ -rich nanoworms regulated by oleyl amine, which effectively stabilizes Fe 2+ . These nanoworms exhibited exceptional efficacy in producing ROS through high Fe 2+ proportion and glutathione (GSH) consumption by Fe 3+, thereby initiating lipid peroxidation (LPO) and subsequent induction of ferroptosis and immunogenic cell death. The conjugation with tumor-penetrating peptide (iRGD) endowed the accumulation at tumor sites. After coupling with αPD-L1, these nanoworms significantly enhanced their tumor inhibition rate through the combination of ferroptosis and immunotherapy, reducing the tumor volume to 22.52%. This work provides a promising material for combined tumor therapy by inducing ferroptosis and downstream immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ferroptosis and cancer prognosis · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Materials Science and Engineering
Zhejiang University of Technology
State Key Laboratory of Natural Medicines, School of Pharmacy
China Pharmaceutical University
Funding
Fundamental Research Funds for the Provincial Universities of Zhejiang · National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province
References (31)
Show source-provided references
1. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
2. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
3. 10.1016/j.molcel.2023.08.00410.1016/j.molcel.2023.08.004 ↗
4. 10.1021/es200274810.1021/es2002748 ↗
5. 10.1038/s41467-022-31218-210.1038/s41467-022-31218-2 ↗
6. 10.1016/j.molmed.2021.06.01410.1016/j.molmed.2021.06.014 ↗
7. 10.1016/j.cej.2022.14068810.1016/j.cej.2022.140688 ↗
8. 10.1016/j.snb.2022.13270710.1016/j.snb.2022.132707 ↗
9. 10.1016/j.apmt.2022.10155810.1016/j.apmt.2022.101558 ↗
10. 10.1016/j.biomaterials.2020.12053010.1016/j.biomaterials.2020.120530 ↗
11. 10.1021/jacs.1c0747110.1021/jacs.1c07471 ↗
12. 10.1186/s12951-022-01635-y10.1186/s12951-022-01635-y ↗
13. 10.3390/nano1311171910.3390/nano13111719 ↗
14. 10.1038/s41598-024-82917-310.1038/s41598-024-82917-3 ↗
15. 10.1016/j.jhazmat.2022.13042610.1016/j.jhazmat.2022.130426 ↗
16. 10.1002/adhm.20210078010.1002/adhm.202100780 ↗
17. 10.1016/j.cej.2023.14296010.1016/j.cej.2023.142960 ↗
18. 10.1016/j.cej.2023.14435810.1016/j.cej.2023.144358 ↗
19. 10.1021/acssuschemeng.2c0714110.1021/acssuschemeng.2c07141 ↗
20. 10.1021/acssuschemeng.8b0572710.1021/acssuschemeng.8b05727 ↗
21. 10.1039/D2NH00111J10.1039/D2NH00111J ↗
22. 10.1021/nl500776e10.1021/nl500776e ↗
23. 10.1002/anie.20201441510.1002/anie.202014415 ↗
24. 10.1042/BCJ2020060210.1042/BCJ20200602 ↗
25. 10.1007/s11426-021-1208-610.1007/s11426-021-1208-6 ↗
26. 10.1021/acs.analchem.3c0543010.1021/acs.analchem.3c05430 ↗
27. 10.1002/adhm.20230129210.1002/adhm.202301292 ↗
28. 10.1093/neuonc/noac03310.1093/neuonc/noac033 ↗
29. 10.1002/cac2.1225010.1002/cac2.12250 ↗
30. 10.1016/j.apsb.2020.10.00910.1016/j.apsb.2020.10.009 ↗
31. 10.1021/jacs.4c0565010.1021/jacs.4c05650 ↗